Cosmo Pharmaceuticals N.V.
CMOPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $267 | $93 | $102 | $65 |
| % Growth | 187.5% | -9.1% | 56.9% | – |
| Cost of Goods Sold | $20 | $39 | $19 | $15 |
| Gross Profit | $247 | $53 | $83 | $50 |
| % Margin | 92.6% | 57.6% | 81.6% | 76.7% |
| R&D Expenses | $0 | $19 | $16 | $11 |
| G&A Expenses | $6 | $5 | $3 | $2 |
| SG&A Expenses | $7 | $5 | $4 | $3 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $90 | $23 | $36 | $7 |
| Operating Expenses | $98 | $47 | $55 | $21 |
| Operating Income | $149 | $6 | $28 | $11 |
| % Margin | 55.8% | 6.6% | 27.5% | 17.1% |
| Other Income/Exp. Net | $4 | -$5 | -$4 | $13 |
| Pre-Tax Income | $153 | $2 | $24 | $24 |
| Tax Expense | $20 | $6 | $7 | $2 |
| Net Income | $133 | -$5 | $17 | $22 |
| % Margin | 49.9% | -5.3% | 16.9% | 33.3% |
| EPS | 8.15 | -0.31 | 1.05 | 1.29 |
| % Growth | 2,729% | -129.5% | -18.6% | – |
| EPS Diluted | 8.12 | -0.31 | 1.05 | 1.28 |
| Weighted Avg Shares Out | 16 | 16 | 16 | 17 |
| Weighted Avg Shares Out Dil | 16 | 16 | 16 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $4 | $3 | $3 |
| Interest Expense | $0 | $9 | $9 | $9 |
| Depreciation & Amortization | $12 | $14 | $13 | $7 |
| EBITDA | $166 | $20 | $47 | $18 |
| % Margin | 62.1% | 21.2% | 45.8% | 27.4% |